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This report addresses the extremely important area of epilepsy in 
the field of intellectual disability (ID), also known as learning disability. 
Epilepsy and ID are two conditions that carry stigma and can lead to 
social isolation. An individual who experiences both these problems 
faces huge challenges. 
Anti-epileptic drugs (AEDs) are the main form of treatment for epilepsy. 
In people with ID, response to treatment can be poor and surgical 
options are limited. Approximately 20–25% of people with ID have 
seizures. With increasing severity of ID, the association of seizures 
and other physical conditions rises. People with ID constitute nearly 
25% of the total population with epilepsy and 60% of the population 
with treatment-resistant epilepsy. Mortality rates due to epilepsy are 
recognised to be higher among people with ID than in the general 
population. The economic impact of providing treatment is significantly 
higher than in the general population. People with ID are five times 
more likely to present to emergency departments for seizure-related 
problems.
Epilepsy care in recent years has seen a large range of evidence-
based treatments and interventions. As expectations held by people 
with ID and their families with regard to services rise, there has 
simultaneously been a transformation in thinking about how people 
with ID should be treated in the context of vulnerabilities arising from 
cognitive deficits, social exclusion and the high rate of comorbidity. 
Epilepsy management is recognised as a core skill needed by psy-
chiatrists working with people with ID. It is vital that psychiatrists for this 
population understand the complexities of their physical and mental 
health needs. This includes interactions between AEDs and other 
commonly used medication and knowing how to identify and manage 
side-effects. In addition, they need to make difficult choices for people 
who struggle to make their own decisions and have problems in 
communication. All this must be achieved while ensuring a satisfactory 
quality of life for their patients. 
I welcome this report, which has put together a clear, useful and 
detailed evidenced-based practical prescribing guide that will improve 
the lives of people unfortunate enough to have both ID and epilepsy. 
Professor Wendy Burn
President, Royal College of Psychiatrists
Foreword
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This report aims to provide epileptologists, psychiatrists, doctors 
and clinicians working with people with ID and epilepsy an overview 
of good practice prescribing. Its focus is on using current evidence 
and applying it to support practical prescribing for people with ID. 
The document is not a substitute for recognised prescribing guides 
such as the British National Formulary (BNF). It is not a complete 
or comprehensive overview of epilepsy management or of epilepsy 
service provision. The contents of this report need to be considered 
as guidance, especially where most practitioners struggle when the 
evidence does not inform the complex clinical challenges. The report 
is a consensus statement on the application of current evidence 
used in the general population to people with ID and should be used 
for the purpose of guiding holistic decision-making in prescribing 
AEDs. It is important that clinicians keep themselves up to date 
using the latest information on the subject as part of their continuing 
professional development, as the subject area covered by this report 
changes rapidly. 
Scope of this report
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The most vulnerable people in society deserve 
the best healthcare. The recent release of 
the national Stopping Over-Medication of 
People with a Learning Disability, Autism 
or Both (STOMP) pledge was a significant 
contribution in giving direction to the manner 
in which prescribing should happen for people 
with ID. Although STOMP concerns itself with 
psychotropics it has opened the door to the 
possibilities and potential for other medical 
specialties to follow suit in the way they take 
care of people with ID.
People with ID have much higher rates of 
epilepsy than the general population, their 
epilepsy is more difficult to diagnose and treat, 
is more likely to be treatment resistant and 
require polypharmacy, and patients may find it 
harder to communicate their needs and wishes. 
The evidence for the efficacy of treatments in 
this subpopulation is less strong. Together, 
these factors culminate in higher premature 
mortality and morbidity rates among people 
with ID and epilepsy.
The limited current evidence on AEDs is most 
supportive of sodium valproate and lamotri-
gine, moder ate for topiramate, gabapentin, 
perampanel, levetiracetam, rufinamide and 
lacosamide, and does not support the use of 
vigabatrin, phenytoin and phenobarbitone. 
Carbamazepine too has very limited evidence, 
but has real-world experience and use in its 
support. Benzodiazepines are very useful as 
rescue medication and for short-term use, but 
rarely beneficial in long-term use. Specific 
exclusions apply for a number of AEDs that 
have been shown to be of more value in treating 
certain rare conditions associated with ID and 
epilepsy. Many of the newer AEDs need further 
research before an informed judgement can 
be made. A ‘traffic light system’ using current 
evidence and expert views has been put in 
place for commonly used AEDs to highlight 
specific advantages and disadvantages for use 
in people with ID.
When prescribing AEDs, start with a low dose 
and titrate upwards slowly. The priority must 
be to minimise side-effects during initiation 
of the drug, so that patients and carers gain 
confidence in it. We propose algorithms based 
on evidence in focal and generalised seizures. 
The safety of the patient should be considered 
before treatment efficacy and outcomes, and 
we propose 10 guiding principles of prescribing 
for people with ID.
Difficulties in diagnosing epilepsy in people with 
ID arise because of physical and psychiatric 
comorbidity, complex behaviours, difficulties 
performing investi gations and challenges in 
communication. In addition, patients are more 
likely to have comorbid mental illnesses and 
are at greater risk of iatrogenic harm from 
treatment. We highlight the common issues 
that should be considered by any prescriber 
of AEDs for people with ID, including special 
subpopulations of autism and dementia.
People with ID are more vulnerable to, but less 
able to communicate, side-effects of AEDs. 
These include effects on cognition (phenytoin 
and topiramate), weight gain (valproate, 
gabapentin and pregabalin), weight loss 
(topiramate and zonisamide) and osteo porosis 
(multiple AEDs). These medications can also 
cause behavioural disturbances, and certain 
AEDs show differences between different 
brands of the same drug, and awareness of 
these needs to inform prescribing. Clinicians 
should also remember the risk of drug 
interactions, especially between different AEDs 
and with psychotropics and contraceptives. We 
provide a framework for considering this. The 
relevance of genetic testing is also presented. 
Executive summary
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Psychotropic medications , especially anti-
psychotics, can increase the risk of seizures. 
First-generation antipsychotics confer a 
marginally greater risk than second-generation, 
and aripiprazole has the lowest risk of inducing 
seizures. Antidepressants are less risky, but 
those that are most sedating are most likely 
to lower the seizure threshold. Tricyclic anti-
depressants and monoamine oxidase inhibitors 
(MAOIs) are best avoided as selective serotonin 
reuptake inhibitors (SSRIs) have lower risks in 
epilepsy. Lithium can cause seizures in over-
dose. Remember the interactions between 
psychotropic medications and AEDs. We give 
an overview of these. 
Every effort should be made to communicate 
information in a person-centred manner 
with patients and carers. Patients should be 
reviewed at least annually and, if changes 
are being made to AEDs, preferably every 3 
months. If patients are on three or more AEDs, 
clinicians should be more vigilant. They should 
also be alert to any changes in the patient’s 
health risk status. If the individual lacks 
decision-making capacity, their best interests 
must be considered. This would include the 
benefits versus the risks of changing AEDs. The 
clinician should rationalise what a proposed 
change is expected to achieve, taking into 
account the potential for success, history of 
previous AED failures, treatment resistance, 
side-effect sensitivity, patient and family/carer 
experience, etc. Any change from one AED to 
another should involve an overlap of titrated 
medication to avoid the risk of seizures. The 
presence of ID does not exclude attempts to 
withdraw anti-epileptic medication, but this 
should be done with caution and close medical 
monitoring. This report provides practical 
guidance on initiation, monitoring, reviewing, 
switching and withdrawing of AEDs in people 
with ID. 
Psychiatrists are in an excellent position to 
improve the management of epilepsy in people 
with ID. They are holistic and comprehensive in 
their approach, have good communication skills 
and are aware of pharmacological complexity. 
Importantly, they work within multidisciplinary 
teams and have a good understanding of 
psychological and social issues that require 
addressing in illness management. There is 
need for further research on the use of AEDs 
in people with ID, and hopefully psychiatrists 
will lead this research with their neurological 
and neuroscience colleagues.
Every attempt has been made to ensure that 
the best-quality evidence and experts in the 
field were consulted in the preparation of 
this report. Their feedback and input has, in 
our view, made the report consistent, richer, 
holistic and person-centred. This document is 
an effort to provide a pragmatic and practical 
bridge over the yawning gap in evidence in this 
area. Its principal purpose is to help colleagues 
working with people with ID and epilepsy to 
be aware of current issues and concerns and 
to encourage them to take a more active and 
informed role in all-inclusive management not 
just of the ID-related problems or the epilepsy, 
but of the individual’s overall care. This report, 
however, is not a substitute for a definitive 
prescribing guide such as the British National 
Formulary (BNF), which should form the 
bedrock of any prescribing. We recommend 
that complex case management involving 
particular medication matters be carried out 
in consultation with a pharmacist and, where 
possible, discussed with a peer group.
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The following principles should be kept in mind when prescribing 
AEDs for people with ID.
1 Follow best practice guidelines for the diagnosis of epilepsy and 
make reasonable adjustments to ensure access to the necessary 
investigations, including genetic testing if it might be informative.
2 Deliver person-centred care and consider the needs and wishes 
of the individual.
3 Consider providing longer clinic appointments.
4 Try to provide individuals and carers with suitable information 
at a level they can comprehend, such as easy-read literature.
5 If the individual lacks the mental capacity to make informed 
choices, consult with key stakeholders in the person’s best 
interests and provide relevant information on medication, 
especially its effects and side-effects.
6 Define seizure improvement for the individual and agree on a 
method of monitoring and reporting it.
7 Make medication choices informed by the evidence base 
described in this report – tailor medication to the individual’s 
particular diagnosis and syndrome, and consider comorbidities 
and other current medication.
8 If medication is ineffective, consider alternative diagnoses, 
including non-seizure related movements that mimic epilepsy 
(such as tics), stereotyped behaviours of autism, and non-
epileptic attack disorder.
9 Set in place ways of gathering feedback, including effect on 
mood, behaviour and social life, to be considered at regular 
structured reviews.
10 If the individual lacks capacity and is showing treatment 
resistance or there is ambiguity regarding the role of medication, 
strongly consider convening a best interests meeting. Key 
stakeholders should include family/carers/independent mental 
capacity advocate, general practitioner, other health and social 
professionals. The person’s wishes need to be gathered as best 
as possible to inform the meeting. Questions to consider include: 
What is the current situation? Is treatment change warranted 
now? If so, what? If not, why not? When would change to the 
individual’s AEDs be needed in the future and why? Records must 
be kept and the decisions re-visited at a set and agreed time.
This is not an exclusive list. Other patient-centred factors that should 
be considered are outlined in this document, and each guiding 
principle is discussed in more detail. 
Guiding principles
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There is a strong association between epilepsy and ID and both may 
be linked to a wide range of pathological processes (Forsgren et al, 
1990; Bowley & Kerr, 2000; Lhatoo & Sander, 2001). The prevalence 
of epilepsy in the general population is between 0.5 and 1% (De 
Boer et al, 2008). In contrast, 20–25% of individuals with ID have 
epilepsy (Ring, 2013; Robertson et al, 2015). There is also a direct 
proportional relationship between severity of ID and prevalence of 
epilepsy (Richardson et al, 1981; Steffenburg et al, 1995). Up to 50% 
of people with moderate to profound ID have epilepsy, and half of 
these are resistant to treatment with current AEDs (Ring, 2013).
Epilepsy results in significant morbidity and mortality and has a wider 
impact on the individual’s everyday life and on family and caregivers 
(Hannah & Brodie, 1998). Alongside aspiration pneumonia, seizures 
are the leading cause of preventable death in the population with ID and 
the main cause of potentially avoidable hospital admissions (Rodway 
et al, 2014). The two major epilepsy-related causes of death among 
people with ID are sudden unexplained death in epilepsy (SUDEP) 
and status epilepticus, which are significantly overrepresented in this 
population (Kiani, 2014; Devinsky et al, 2016). 
Understanding the complexity and individual needs of people with ID 
highlights some of the barriers they face in accessing appropriate care 
and treatment (Table 1). Communication problems affect the reliability 
of assessments and diagnosis. Clinicians often have to consider 
treatment options in cases where individuals lack the capacity to 
make informed decisions regarding their treatment. The ID population 
also has significantly higher levels of comorbid mental and physical 
disorders, which may influence treatment choices (Cooper et al, 2007; 
Kwok & Cheung, 2007; Heslop et al, 2013). There are no specific 
national guidelines for ID, but both the National Institute for Health and 
Care Excellence (NICE) and the Scottish Intercollegiate Guidelines 
Network (SIGN) recognise the problem with prescribing for this group. 
Two previous documents have reviewed prescribing for epilepsy in 
people with ID and reached a consensus on management (Working 
Group of the International Association of the Scientific Study of 
Intellectual Disability, 2001; Kerr et al, 2009). Both conclude that there 
is a dearth of high-quality evidence from well-constructed studies 
on which to base definitive guidance. The potential adverse effects 
of AED treatment on cognition and behaviour are not considered 
specifically in the population with ID in current national guidelines. 
Equally, the practical nuances of administering certain drugs in this 
vulnerable population needs highlighting. It is also worth noting that 
different drugs have different levels of evidence of efficacy on seizures 
Background
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in people with ID. Other neurodevelopmental, cognitive, mental and 
physical comorbidities may also influence seizure presentation and 
the choice of medication, its side-effects and outcome. 
There is a clear need for a consensus document to provide an 
overview of the current evidence base for the prescription of AEDs 
for people with epilepsy and ID. There is also a need to identify the 
gaps in our knowledge of prescribing to ensure that clinicians, people 
with ID, carers and families are fully informed of the benefits and risks 
associated with prescribing, or advising against, treatment. This report 
will largely focus on providing practical and good practice advice on 
prescribing of anti-epileptic medication. 
When considering when and how to treat seizures the current 
evidence must be taken into account. There is limited robust research 
involving people with epilepsy and ID. The choice of medication 
is therefore largely based on data extrapolated from randomised 
controlled trials (RCTs) in the general epilepsy population. Only a 
few seizure syndromes (epileptic encephalopathies) associated with 
the development of ID have had specific research. These include 
Lennox–Gastaut and Dravet syndromes, which are associated with 
treatment-resistant epilepsy, drug sensitivity, frequent seizures and 
multiple seizure types, for which an evidence base for guidelines 
exists (Guerrini et al, 1998; Besag, 2011). 
An authoritative report published in 2014 proposed a framework for 
enhancing the delivery of support for people with epilepsy and ID and 
Table 1 Common features of epilepsy in people with ID in comparison 
with the general population
 z Seizures are usually present in early life
 z Higher rates of genetic/structural brain damage, with generalised 
rather than complex partial seizures being the most common
 z Less likely to be seizure free on first treatment and more likely to 
have life-long seizures
 z More sudden unexpected death in epilepsy (SUDEP) and status 
epilepticus
 z Higher rates of AED prescription and polypharmacy
 z Higher risk of status epilepticus and thus more likely to be on an 
emergency rescue protocol
 z Increased rates of attendance at emergency departments
 z Multi-morbidity
 z Individuals may have limited ability to communicate and make 
treatment choices
 z No clear mechanism of measuring treatment ‘success’
 z Specific problems with chewing, swallowing, constipation and 
percutaneous endoscopic gastrostomy (PEG) feeding
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identified four major areas of concern (Kerr et al, 2014). One of the 
areas highlighted was diagnosis and medical treatment. The report 
emphasised specific concerns about the prescription of AEDs and 
the identification and monitoring of side-effects. As part of a strategic 
response, in May 2017 the Royal College of Psychiatrists’ Faculty of 
Intellectual Disability produced a College Report (CR203) highlighting 
good practice in the management of epilepsy in adults with ID (Royal 
College of Psychiatrists, 2017). The report called for further specific 
advice on the prescription of AEDs for people with epilepsy and ID. 
The current report on prescribing AEDs for people with ID is the 
‘next step’ in this strategy to improve the standard of epilepsy-related 
healthcare for this vulnerable group. The scope of this report is to 
establish best practice for the management of epilepsy with AEDs and 
the identification of their side-effects. Specific attention will be paid to 
addressing drug interactions because of the high level of comorbid 
conditions in this population. This summary of the evidence will help 
inform prescribing clinicians in relation to the attaining the Bronze/
Silver/Gold competencies laid out in CR203.
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The Royal College of Psychiatrists’ Faculty of Intellectual Disability 
notes that an understanding of prescribing for people with epilepsy 
is essential to the role of a psychiatrist working with such individuals 
(Royal College of Psychiatrists, 2017). 
Objectives
 z To identify the current evidence base on prescribing AEDs to 
people with ID 
 z To identify the general and specific needs and requirements of 
people with ID who have epilepsy, with particular focus on the 
impact of AEDs
 z To identify and deliver a framework for evaluating current AEDs, 
bringing together evidence and expert clinician perspective 
 z To identify a prescribing framework for psychiatrists treating or 
being consulted about a person with ID and epilepsy
 z To give an overview of the complex side-effects of AEDs and 
possible ways to mitigate them
 z To highlight the practical pitfalls in co-prescribing, including 
drug interactions with other commonly prescribed psychiatric 
medication
 z To provide a document that psychiatrists might use to measure 
their current ability to manage epilepsy in people with ID and to 
develop epilepsy competencies as proposed in CR203 (Royal 
College of Psychiatrists, 2017)
 z To provide a template for a national dialogue with other key health 
professionals, including specialist epilepsy nurses, neurologists 
and GPs, with the aim of developing a unified strategy for 
treatment and management of epilepsy in people with ID to 
help improve outcomes
Methodology
A recent study (Ford & Norrie, 2016) highlighted concerns that clinical 
trials are inadequate to inform routine clinical practice, as trial settings 
are usually unrepresentative of real-life scenarios. There are concerns 
that clinical trials underestimate the harms while overestimating the 
Objectives and 
methodology
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benefits of interventions. There is a call to deliver evidence using 
pragmatic real-world information with gold-standard proof. Evaluation 
of effectiveness needs a broad view to ensure that interventions are 
safe, beneficial and cost-effective in subgroups of the population.
The Advisory Committee of this report recognised that there is a 
paucity of good evidence for prescribing AEDs for people with ID. 
However, as there is a growing need to provide practical direction, 
an attempt has been made here to combine published evidence with 
the everyday practice of experts in the field to provide a practical 
guide to prescribing for this population. Development of this report 
was carried out as follows.
Step 1 – A focused literature review by the Deputy Editor and Editor 
using recent publications (e.g. Kerr et al, 2014, 2016; Jackson et al, 
2015; Doran et al, 2016; Shankar et al, 2017a,b). They also reviewed 
and analysed best practice documents from organisations such as 
NICE and SIGN, and recent government White Papers about epilepsy 
and ID.
Step 2 – The Deputy Editor and Editor wrote a draft report that 
included a proposal for systems of rating AEDs using a traffic light 
system.
Step 3 – Circulation of the draft report and extensive feedback from the 
Advisory Committee (comprising three expert neurologists specialising 
in epilepsy, including two academics; one specialist epilepsy nurse; 
four specialists in ID and epilepsy; one GP; one pharmacist; one 
consultant in general adult psychiatry; and three consultants in 
ID). Feedback was collected and assimilated into the developing 
document and plan. The Advisory Committee represented a diverse 
group of experts in research methodology, research in ID and AEDs, 
research in epilepsy and clinical experts. 
Step 4 – An update on the planned structure of the document was 
presented at a meeting of the Royal College of Psychiatrists’ Intellectual 
Disability Faculty Executive. Approval was gained to continue in the 
direction identified and specific issues were highlighted.
Step 5 – The report was circulated to all Advisory Committee members 
for comments and feedback.
Step 6 – The Faculty of Intellectual Disability submitted the report 
to the College for stakeholder feedback. It was disseminated to all 
divisions and faculties; the Psychopharmacology Committee, Northern 
Ireland Faculty and Faculty of Old Age Psychiatry returned comments. 
Step 7 – Feedback received from these stakeholders was incorporated 
to produce the final report.
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The decision of when and how to treat epilepsy should take into 
consideration the impact of seizures on the patient versus the potential 
positive and negative effects of medication. Treatment with AEDs 
may not be straightforward; there is the potential for side-effects, 
toxicity and pharmacological interaction with other drugs. A clear 
diagnosis of a seizure disorder must be established before initiating 
pharmacological treatment. Prescribing clinicians should refer to 
standardised national guidelines for the management of epilepsy 
from NICE (CG137: NICE, 2012) and SIGN (SIGN 143: SIGN, 2015). 
These guidelines are based on the same evidence and there are 
significant overlaps in recommendations. The NICE CG137 guidelines 
are referred to throughout this report and we attempt to extend 
advice beyond the scope of those recommendations. We put forward 
further recommendations that argue that the treatment of people with 
epilepsy and ID requires specific consideration and guidance owing 
to the complexity of need.
The assessment of suspected seizures in an individual with ID may be 
complicated by their level of cognition and communica tion. As a result, 
the clinician may be reliant on witness reports from family members 
or caregivers. The degree of dependence on this information will be 
influenced by the level of adjustments that both clinicians and services 
put in place to help communication with the individual. Although 
the diagnosis of epilepsy is based on the history and eye-witness 
reports, people with epilepsy and ID should have access to the full 
range of electrophysiological investigations and neuroimaging to aid 
assessment and improve accuracy of diagnosis, if this is appropriate. 
The use of video electroencephalogram (EEG) and telemetry can be 
particularly useful for this population (Kerr et al, 2001).
When considering treatment options it is essential to adopt a person-
centred approach. Seizure type, seizure syndrome and, importantly, 
patient and carer choice must all be evaluated. Clinicians should aim to 
profile treatment to take into account specific aetiological risk factors. 
There is a relatively high incidence of treatment-resistant epilepsy in the 
ID population. Making an evidence-based informed decision about the 
most appropriate first-line pharmacological therapy is essential. The 
most recent Cochrane Review highlights that to date the evidence of 
the efficacy of specific AEDs in people with ID is generally poor and 
there are limited robust reproducible outcomes (Jackson et al, 2015).
Most data on the pharmacological treatment of epilepsy in the ID 
population are derived from open or observational non-randomised 
trial designs. The results from such trials are open to methodological 
Summary of evidence
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criticism and hence interpretation is difficult. There are some exceptions 
to this. Infantile spasms, Dravet syndrome and Lennox–Gastaut 
syndrome are common epilepsy syndromes strongly associated with 
ID, and there has been more extensive pharmacological research into 
the efficacy of treatment in these syndromes (Table 2). 
Table 2 Examples of common epilepsy syndromes associated with ID
Epilepsy syndrome Evidence for AED role
Dravet syndrome 
(severe myoclonic epilepsy)
Lamotrigine, phenytoin and 
carbamazepine can aggravate seizures 
(Guerrini et al, 1998)
Lennox–Gastaut syndrome Rufinamide was suggested as offering 
most benefit (Besag, 2011)
Lamotrigine was linked to significant 
seizure reduction and improvement in 
mood, sociability (Motte et al, 1997)
Clobazam has had two randomised 
controlled trials and is suggested to be 
a good adjunct for drop attacks (Conry 
et al, 2009; Ng et al, 2011) 
Topiramate has been recognised 
to have an effect on drop attacks 
(Sachdeo et al, 1999)
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Benzodiazepines
There is good evidence to support the use of benzodiazepines (e.g. 
clonazepam, clobazam, diazepam and midazolam) as emergency 
rescue and add-on medication in treatment-resistant epilepsy. 
Midazolam is used extensively to curtail seizures outside of the hospital 
setting (Walker & Shrovon, 2015), and clobazam is regularly used for 
people with ID. 
Benzodiazepine treatments have been criticised for potential adverse 
side-effects, including cognitive impairment in long-term use in 
both general and ID populations, and as a result are favoured more 
for use as rescue treatments (Isojärvi & Tokola, 1998). The use of 
benzodiazepines is limited in the presence of cognitive deficit or 
behavioural disorder. Tolerance is a major concern in people with 
ID: they might not have active medication reviews and would not 
be aware of a need for one; a benzodiazepine might have been 
prescribed for behaviour management and not withdrawn; and if 
multiple AEDs are prescribed, benzodiazepine tolerance might not 
manifest as increased seizures. It has been suggested that around 
30% of people with epilepsy on clobazam could continue without 
developing tolerance (Remy, 1994; Purcarin & Ng, 2014). The potential 
downsides of tolerance include the distress of changing medication 
and the need to reduce slowly if tolerance occurs. 
Another risk is that significant numbers of people with ID find 
themselves on various benzodiazepines to treat behaviour, mood 
or anxiety. Clinicians must be aware of the overall ‘benzodiazepine 
load’ when prescribing clobazam and other benzodiazepines and 
monitoring for seizures. 
To date, there are no definitive studies or recommendations to guide 
treatment using this group of drugs in people with ID. 
Clobazam
Clobazam has an evidence base especially in Lennox–Gastaut 
syndrome, and is useful in managing atonic seizures (drop attacks). 
Evidence of the use of 
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It is a unique benzodiazepine as it has a 1,5 benzodiazepine structure 
(the others all have a 1,4 structure) and it is consequently not as 
sedative as the other benzodiazepines. It also has a long half-life 
of 50 hours (active metabolite). It is not a drug to be considered for 
long-term use, but there is evidence to support its use as a rescue 
treatment for cluster seizures, and as an adjunct for all seizure types 
in intermittent short-term treatment (up to 5 days in 15-day cycles) 
(Gauthier & Mattson, 2015). It is therefore the ideal drug to use as a 
rescue medication where there is a known seizure trigger or where 
medication changes are occurring and there is a need for some 
additional ‘cover’. Any long-term regular use has to be weighed 
against the potential of habituation or tolerance, difficulty in withdrawal 
and long-term side-effects. Due consideration needs to be given to 
explaining the benefits versus risks of long-term use and, in those 
lacking mental capacity to make informed choices, a best interests 
process is advocated.
Carbamazepine
The evidence for prescribing carbamazepine in ID populations is poor. 
There are no direct studies on the effect of the drug in people with ID. 
A double-blind RCT reported possible better efficacy in people with 
ID for slow-release preparations as opposed to regular preparations 
(Kaski et al, 1991). Carbamazepine is known to have a number of 
adverse effects; the most common of these is hyponatraemia in up to 
40% of people taking the drug. Other side-effects include drowsiness, 
nausea and vomiting, dizziness and bone marrow suppression. 
Carbamazepine can also interact with many other drugs prescribed 
for chronic conditions. As a result of these potentially ‘silent’ side-
effects and interactions it needs to be used with caution in people 
with moderate to profound ID. This vulnerable group with epilepsy are 
likely to be treatment resistant and to have multiple chronic conditions 
treated with numerous medications, all of whose interactions might 
need to be kept in mind. 
Clobazam: see Benzodiazepines
Gabapentin and vigabatrin
The efficacy and safety of gabapentin (in comparison with lamotrigine) 
were assessed in a randomised open-label study involving 109 adults 
with ID and treatment-resistant epilepsy (Crawford et al, 2001). Safety 
and tolerability were assessed using adverse event reports. The overall 
incidence of adverse events was similar across the treatment groups, 
with adverse events reported for 62% of participants on gabapentin 
and 50% on lamotrigine; serious adverse events were reported for 
10% on gabapentin and 11% on lamotrigine. This was the first-reported 
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randomised trial for add-on anti-epileptic medication in people with 
epilepsy and ID. It concluded that both drugs were effective for seizure 
control and that neither caused significant worsening of behaviour 
as evidenced using the Whelan & Speake Challenging Behaviour 
Rating Scale. 
A case review of the first 51 people with Lennox–Gastaut syndrome 
prescribed vigabatrin, lamotrigine or gabapentin suggested that all 
three had some positive effect on seizure control. Vigabatrin was 
associated with higher risk of adverse effects on behaviour, and 
lamotrigine was associated with increased seizures in a quarter of 
participants (Bhaumik et al, 1997). Vigabatrin had previously been 
associated with the development of visual field defects, but the review 
does not comment on this. The prescribing of vigabatrin for people 
with ID raises serious ethical concerns, as the BNF states that all 
patients prescribed vigabatrin must be made fully aware of the risk 
of visual field defects and how to report these to their physician.
Levetiracetam
To date, levetiracetam has not undergone an RCT within the ID 
population. A number of open-label studies have demonstrated 
that it is effective and equally well tolerated in individuals with ID. In 
one open study, 64 people were given add-on levetiracetam after 
a 3-month baseline (Kelly et al, 2004). Of these, 24 people (38%) 
became seizure free and there were a further 18 responders (≥50% 
reduction in seizures). In general, levetiracetam has been shown 
to be well tolerated. There is an association with neuropsychiatric 
disturbance, particularly aggression. This may, however, be confined 
to those biologically vulnerable with a psychiatric history (Mula et 
al, 2004) and may be the result of rapid dose escalation, as it has 
generally been reported more frequently in neurology clinics than in 
ID clinics.
Lamotrigine
Lamotrigine is a well-tolerated and effective AED for people with ID, 
and it is thought to have mood-stabilising properties. Early research 
involving 34 people with ID showed a significant improvement in 
seizure control in over 50%, with a further 35% becoming seizure 
free (Buchanan, 1995). Results of a randomised open-label study 
investigating the use of lamotrigine and gabapentin in adults with 
ID and treatment-resistant epilepsy suggested that there was an 
approximate 50% reduction in seizures in half of the people receiving 
either drug. Both drugs were equally well tolerated and associated with 
improvements in challenging behaviour. These outcomes have been 
consistently repeated for lamotrigine in a number of more recent case-
series studies. A proportion of the population with treatment-resistant 
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epilepsy have, however, shown no improvement in seizure control 
(Bhaumik et al, 1997; Gidal et al, 2000). Lamotrigine has also been 
subject to the most rigorous quality-of-life evaluation in people with 
Lennox–Gastaut syndrome, during a randomised placebo-controlled 
add-on trial with 169 participants. An improvement in seizure control 
was observed, with a significant reduction in atonic seizures (drop 
attacks) and total seizures. Outcomes also demonstrated significant 
improvement in mood and sociability associated with reduced seizure 
severity, but no difference in side-effect profile when compared with 
placebo (Motte et al, 1997). In comparison studies with carbamazepine 
and phenytoin, lamotrigine has been found to produce positive 
behavioural effects, but it has also been reported that lamotrigine 
can produce some neurobehavioural toxicity (Meador & Baker, 1997).
Perampanel
A recent multi-centre pragmatic retrospective assessment found that 
perampanel is safe and may be better tolerated by people with ID 
than the general population (Shankar et al, 2017b). Over 50% seizure 
improvement was observed in 24% of those with mild ID, and in 
26% of those with moderate to severe ID. There is a suggestion that 
perampanel should be used with caution in individuals with underlying 
(or a history of) mental illness as there is an increased risk of worsening 
of their behaviour and mental state. 
Phenytoin
The current recommendations suggest that phenytoin should not 
be prescribed for people with ID unless it is considered to be in the 
patient’s best interests. Those prescribed phenytoin require close 
monitoring in order to prevent intoxication and subsequent phenytoin-
induced encephalopathy (Iivanaien, 1998). Poor monitoring can result 
in toxic levels, which may manifest as cerebellar ataxia, drowsiness 
and cognitive decline. This is a potential difficulty for some people with 
ID who are unable to tolerate the regular venepuncture required for 
long-term routine monitoring. Phenytoin also has multiple significant 
interactions with other drugs. As a significant minority of people with 
ID are on various long-term medications, the potential for dangerous 
drug interactions could be greater.
Sodium valproate
Sodium valproate has been widely used as a broad-spectrum AED 
for over 40 years, with a relatively good safety profile (Nalivaeva 
et al, 2009). Some research has demonstrated that people with ID 
who have treatment-resistant epilepsy may be more responsive to 
valproate. Valproate is a first-line treatment for primary generalised 
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seizures and syndromes, as it is generally well-tolerated and effective 
in treating a variety of seizure types (Friis et al, 1993). The SANAD 
study compared the longer-term effects of valproate in people with 
generalised seizures and seizures difficult to classify, such as those 
seen in many people with ID. It found that the 12-month remission 
rate of seizures with valproate was significantly greater than with 
topiramate, but no significant difference was identified between 
valproate and lamotrigine. This effect was greater when the analysis 
was restricted to people classified as having idiopathic generalised 
epilepsy compared with the overall population. It was concluded 
that valproate ought to remain the first-line treatment for the majority 
of people with idiopathic generalised epilepsy or seizures which are 
difficult for the clinician to classify (Marson et al, 2007). Limitations to 
the use of valproate in the general population relate to its teratogenic 
potential, and it often causes weight gain (Hannah & Brodie, 1998). 
There are also concerns about its use in some people who have rare 
causes of ID and epilepsy such as mitochondrial disease and ornithine 
transcarbamylase deficiency.
Topiramate
The efficacy of topiramate has been investigated in a randomised 
placebo-controlled add-on study with 57 participants with epilepsy and 
ID (Kerr et al, 2005). Seizure frequency varied significantly among the 
participants, but an overall reduction in frequency of 32% was noted 
in the topiramate group (compared with 1% for placebo). Topiramate 
was found to be generally well tolerated and did not have a negative 
impact on behaviour. Very few participants withdrew from the study 
because of adverse effects of medication, and the study suggested 
that topiramate reduced seizure rates without compromising quality 
of life. A small review has examined the treatment response to 
topiramate in an institutionalised adult ID population (Janowsky et 
al, 2003). The results suggest that topiramate may have a role in the 
treatment of challenging/maladaptive behaviours in people with ID 
when used as an add-on medication for the treatment of partial and 
generalised seizures. Another review of the effectiveness of topiramate 
in individuals with ID and epilepsy found that the drug was effective 
for a wide range of seizure types (generalised and partial) and was 
effective against atonic seizures in Lennox–Gastaut syndrome (Kerr, 
1999). Despite this evidence, topiramate is still sparingly used as 
prescribers believe that it causes quite a lot of sedation, word-finding 
difficulty and weight loss. 
Other AEDs
There is some emerging evidence from retrospective open-label 
studies that newer AEDs such as lacosamide may be a useful 
adjunctive therapy for those with ID and treatment-resistant epilepsy. 
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The evidence is, however, very limited to date, and caution is required 
in interpretation (Flores et al, 2012). 
Rufinamide has been assessed in an RCT of people with Lennox–
Gastaut syndrome, in which 138 individuals received either rufinamide 
or placebo. Significant improvements were seen in total seizure 
frequency and atonic (drop) attacks, with a 50% responder rate 
overall. Common adverse events included somnolence and vomiting 
(Glauser et al, 2008). 
To date, evidence of the tolerability or efficacy of AEDs such as 
pregabalin, brivaracetam, tiagabine, stiripentol, ethosuximide, 
eslicarbazepine, oxcarbazepine, retigabine and zonisamide is 
extremely limited in the scientific literature. Stiripentol is an orphan 
drug and would be used only for specific conditions such as Dravet 
syndrome and is best prescribed under expert guidance.
Pregabalin is a well-used ‘multipurpose’ drug having indications in 
the management of pain and anxiety, conditions that are associated 
more often in people with ID. The fact that relief from these conditions 
can have a positive effect on seizures is worth keeping in mind. 
Ethosuximide, tiagabine and retigabine need to be used with extreme 
caution with clear rationale of why they are prescribed and what is 
served by their inclusion. 
There is anecdotal evidence to suggest that zonisamide, if built up 
gradually, has a positive effect on seizures. Cautions include its impact 
on mental state and behaviour. 
Eslicarbazepine and oxcarbazepine are considered to have a favourable 
effect on mood and behaviour. Advantages of eslicarbazepine include 
its dosing recommendations, which allow for swift attainment of a 
therapeutic dose. 
Brivaracetam is a new drug and there is no major evidence yet for 
its use in people with ID.
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The NICE clinical guideline on epilepsies (CG137) states that the 
choice of treatment and monitoring of tolerability and effectiveness 
should be the same for people with ID as for the general population 
(NICE, 2012: section 1.16). Recommendations for the pharmacological 
management of epilepsy are set out in section 1.9 and Appendix E 
of the guideline.
However, while CG137 sets out broad principles of epilepsy treatment, 
the lack of specific consideration of problems associated with ID is 
clear. The guidance does include a section on ID, but it is inadequate. 
Owing to the complexity of the presentation of epilepsy in people 
with ID specific considerations are needed. In general, it is advised 
that AEDs should be prescribed at the lowest possible dose and 
with slow titration. This will aid in accurate assessment of the effect 
of the AED on seizure control and of its side-effects in the context of 
communication difficulties and comorbid mental illness; in particular, 
side-effects may present as behavioural change.
Box 1 summarises internationally recognised criteria for assessing 
the quality of evidence in the medical literature. We use this grading 
Choosing the most 
appropriate AED
Box 1 Grading of evidence
Ia Evidence from systematic reviews or meta-analysis of RCTs
Ib Evidence from at least one RCT
II  Evidence from at least one controlled study without randomisation, 
and from at least one other type of quasi-experimental study
III Evidence from non-experimental descriptive studies, such as 
comparative studies, correlation studies and case–control studies
IV Evidence of post-study analysis of a section of the ID population 
following large sample studies 
V Evidence from expert committee reports or opinions and/or clinical 
experience of respected authorities
(adapted from Canadian Task Force on the 
Periodic Health Examination, 1979; Sackett, 1989)
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system in Table 4 (see next two pages), which provides an overview 
of practical evidence-based prescribing for people with ID. The most 
relevant paper has been cited for each drug. A recommendation is 
given in the form of a traffic light system:
 RED Only use in exceptional circumstances
 AMBER Could be considered if benefits outweigh risks or as 
second-line treatments
 GREEN Needs to be considered as first-line treatment
The traffic light system integrates both clinical experience, evidence 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In general, the most appropriate way to initiate a new AED in the ID 
population is to follow the principle of a low starting dose and slow 
titration. Many experts in the field do so at half or even quarter the 
rates suggested for the general population. This reduces the likelihood 
of dose-related adverse effects. It also allows greater opportunity for 
identifying the minimum effective dose and less chance of missing 
the ‘therapeutic window’, above which worsening of seizure control 
may occur. Individuals may also metabolise drugs at different rates, 
and slow titration is a benefit here too. 
Good practice suggests that a ‘new’ drug is added before the ‘old’ 
drug is withdrawn, in order to ensure that there is no confusion about 
symptoms or changes in epilepsy due to a drug titration. The main 
disadvantage to a cautious introduction is the potential for a lengthier 
time to seizure control. However, most people requiring change have 
treatment-resistant epilepsy and multiple seizures and so a cautious 
approach looking for emergent side-effects outweighs rapid dose 
titration to see whether seizure control can be achieved. In some 
cases, a lengthy titration might result in patients or their families losing 
confidence in the medication, but they should be counselled during 
the consultation process to ensure realistic expectations. 
If rapid seizure control is required, it may be necessary to titrate a new 
drug alongside a ‘rescue medication’ such as clobazam.
Given the significant physical and psychiatric comorbidities that often 
exist in people with ID, medication must be tailored to the individual. 
Procedures such as those identified in the Mental Capacity Act 2005 
for England and Wales, including the best interests process, should 
be used where applicable to ensure that treatment goals are holistic 
and realistic, particularly for people at high risk, such as those with 
drug-resistant epilepsy. Decisions should be representative of the 
individual’s wishes and take into account their quality of life and 
daily activity, while ensuring optimum safety from seizures and their 
side-effects. Communication aids such as ‘easy read’ information or 
speech and language specialists should be considered to help the 
individual to make a treatment choice. 
The flowcharts on the next page outline the procedure for making 
an initial treatment decision (Fig. 1) and for choosing an alternative 






















Fig. 2 Making a treatment choice if monotherapy fails (adapted from Shankar et al, 2017a).
Majority of patients:
clear impact of epilepsy
Convincing story of very brief 
partial seizure with minimal impact 
on health and social function 
No treatment
Consider telehealth  
(light-touch reviews)
Aim for monotherapy










Fig. 1 Making an initial treatment choice (adapted from Shankar et al, 2017a).
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Before prescribing AEDs for people with epilepsy and ID there are a 
number of key considerations (Fig. 3). The first should be to ensure the 
individual’s safety, as treatments and outcomes cannot be guaranteed 
to be successful. This includes carrying out a detailed personalised 
risk assessment of the effects of their epilepsy. Two key risk areas 
to consider are bathing and sudden unexpected death in epilepsy 
(SUDEP). The SUDEP and Seizure Safety Checklist (https://sudep.org/
checklist) is a practical, evidence-based tool that is quickly completed 
in the clinic (Ridsdale et al, 2011; Ridsdale, 2015; Shankar et al, 
2013a; Ostler et al, 2015). It promotes meaningful communication, 
provides a baseline for comparing changes in risk factors over time, 
and supports prioritisation of clinical activity. Ensuring the safety of 
the individual also includes safe prescribing. It is therefore important 
to approach prescribing in a person-centred way, evaluating the risks 
and benefits of AED prescription in the context of seizure profile, 






Fig. 3 The hierarchy of considerations in prescribing AEDs for people with ID.
Considerations when prescribing in ID 29
The aim of any treatment should be to underpin specific holistic 
outcomes based on the individual’s seizure history, comorbidity, 
level of ID and expected quality of life. There are likely to be numerous 
mitigating biological, psychological and social factors that have an 
influence on risk and treatment planning. A thorough environmental 
risk assessment is essential as the individual may well be reliant on 
family or caregivers for support with treatment and risk reduction. 
Epilepsy awareness training should be provided to everyone involved 
in the individual’s care, and where seizure rescue medication is 
prescribed specific training should be given to anyone involved in its 
administration. More detailed information about the wider management 
of epilepsy in people with ID is set out in College Report CR203 (Royal 
College of Psychiatrists, 2017).
The education, observation, treatment goals and management plans 
should be brought together in an overall individualised ‘epilepsy 
management plan’ for each person, ideally formulated in a single 
written plan. This plan can then be shared with the GP, other clinicians 
and the individual’s family and paid carers as appropriate. The key 











• Problems such as 








Fig. 4 Considerations in the person-centred approach to the treatment of people with epilepsy and ID.
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Genetic investigations and AED 
prescribing
Although it is not possible for clinicians to keep up to date with every 
new genetic discovery of an epilepsy-related gene, it is important 
to investigate patients with ID and epilepsy who have no diagnosis 
to account for their comorbid neurodevelopmental disorders. The 
findings from genetic investigations might influence epilepsy treatment, 
including the choice of AED. Identification of an SCN1A mutation in an 
individual presenting with a Dravet syndrome phenotype should lead to 
the avoidance or withdrawal of lamotrigine, phenytoin, carbamazepine 
and other sodium channel-blocking AEDs which can aggravate 
seizures (as mentioned in the Summary of evidence). Instead, AEDs 
such as sodium valproate, clonazepam and stiripentol are indicated. 
A mutation of the SLC2A1 gene (which codes the cerebral glucose 
transporter), in the presence abnormal movements and/or a family 
history of seizures, helps in the diagnosis of glucose transporter 
type 1 (GLUT1) deficiency, which responds very well to a ketogenic 
diet. Some mitochondrial disorders and cerebral creatine deficiency 
syndromes (CCDS) are also associated with ID and epilepsy, and 
may respond to specific treatments. A Cochrane Review (Pfeffer 
et al, 2012) did not identify any evidence-based disease-modifying 
treatments for mitochondrial disorders, but reports are emerging in 
the literature of successful treatment, including seizure reduction in 
some patients with mitochondrial disorders treated with, for example, 
coenzyme Q10 and L-carnitine. L-carnitine has also been used to 
successfully treat seizures in guanidinoacetate methyltransferase 
(GAMT) deficiency, one of the CCDS (Mercimek-Mahmutoglu et al, 
2006; Stockler-Ipsiroglu et al, 2014). Improvements were also seen 
in motor movement, but not in intellectual functioning. 
Genetic testing can also help avoid serious iatrogenic side-effects. The 
recessive polymerase-gamma (POLG) related disorders form part of 
the group of mitochondrial disorders and are commonly associated 
with seizures but have a complex and variable presentation. Sodium 
valproate can cause irreversible liver failure in patients with a POLG 
mutation and consideration should be given to testing people for POLG 
mutations when presenting with seizures and liver dysfunction. Human 
leukocyte antigen (HLA) testing should be considered for patients of 
Han Chinese extraction owing to the significantly increased risk of 
mild to severe life-threatening rashes secondary to carbamazepine 
exposure. For instance, the HLAB*1502 allele is a major risk factor 
in populations of South Asian origin. For all patients with ID and 
epilepsy of unknown cause, clinicians should consider arranging 
micro-array comparative genomic hybridisation (array CGH) testing, 
which is fairly easily available. Specific epilepsy gene panels and 
whole exome sequencing (WES) are available in specialist centres 
only. Diagnosis and treatment of disorders such as CCDS often takes 
place in tertiary centres. Where appropriate, clinicians should liaise 
with regional genetics departments.
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The NICE clinical guideline on epilepsies (CG137) outlines the 
difficulties of diagnosing epilepsy in children and adults with ID (NICE, 
2012). The problem arises because of the multiple comorbidities, 
including stereotypic or other behaviours that may mimic seizures. 
Individuals with ID and epilepsy often have very complex needs and 
a wide range of comorbid physical, neuropsychiatric and behavioural 
difficulties (Cooper et al, 2007). As a result of this complexity these 
individuals have less access to diagnostic investigations and have less 
contact with specialist services than the general epilepsy population 
(Hanna et al, 2002). 
ID and epilepsy are independently associated with an increased risk 
of premature mortality. The combination of ID and epilepsy, together 
with associated physical comorbidity, significantly raises standardised 
mortality ratios (Hitiris et al, 2007; Heslop et al, 2013). Comorbid 
physical health conditions inevitably lead to polypharmacy and the 
increased risk of drug interactions, which could have potentially 
adverse effects for the individual. For example, individuals with ID are 
more susceptible to bone disorders. This may in part be contributed to 
by prolonged immobilisation and vitamin D deficiency (Wagemens et 
al, 1998). There is also clear evidence that AEDs themselves can lead 
to bone density disorders with chronic use (Petty et al, 2005). This 
is of particular importance as people with ID are more likely to have 
refractory epilepsy and be prescribed multiple AEDs for a prolonged 
period. NICE recommends that vitamin D should be prescribed 
proactively in this population (NICE, 2014). 
Epilepsy is also strongly associated with an increased risk of 
mental health problems, and standards have been published for 
the treatment of neuropsychiatric conditions (Kerr et al, 2011) and 
behavioural manifestations (Kerr et al, 2016). In a clinical setting, 
the key is identification and assessment of the association between 
behavioural changes and the seizure disorder. The point prevalence of 
mental illness in the ID population is over 50%, with many individuals 
having more than one diagnosable psychiatric disorder (Cooper et 
al, 2007). People with ID and active epilepsy are also at greater risk 
of developing mental illness (Turky et al, 2011), and it can affect 
epilepsy assessment and treatment. The clinician needs to identify 
whether the mental illness is pre-ictal, ictal, post-ictal or inter-ictal. 
Pre-ictal psychiatric disturbance occurs in the days, hours or seconds 
prior to a seizure and is usually readily identifiable. Ictal disturbance 
in a person with ID is often manifested by the fluctuating levels of 
consciousness seen in non-convulsive status epilepticus. Post-ictal 
Complexity
College Report CR20632
disturbance may be immediate and, in essence, a confusional state, or 
it may have a more severe presentation, such as post-ictal psychosis. 
Inter-ictal psychiatric disturbances are not temporally associated with 
the seizures.
There may be some confusion for clinicians about behaviours that 
are associated with epilepsy and its treatment, and those that 
are not. Differentiating these more complex seizure presentations 
from psychiatric disturbance or non-epileptic seizures can be very 
challenging in the general population. Considering these presentations 
in the ID population is further complicated by the high prevalence 
of repetitive stereotyped motor behaviours (Chebli et al, 2016). The 
role of psychotropic medication that has epileptogenic potential must 
also be carefully considered (Alper et al, 2007). For specific guidance 
on behavioural manifestations and neuropsychiatric management 
for this population see Kerr et al (2011, 2016). A large proportion of 
people referred to specialist epilepsy units have been shown to have 
a misdiagnosis of epilepsy following neurophysiological testing (Donat 
& Wright, 1990; Raymond et al, 1999). 
Autism
It is now well-recognised that rates of epilepsy are higher in people 
with autism than they are in those without the condition, and a variety 
of mechanisms appear to underpin this high comorbidity rate (Buckley 
& Holmes, 2016). In the future, better understanding of the biology 
of these mechanisms, combined with increased knowledge of the 
modes of action of AEDs, may enable the development of a specific 
approach to AED prescribing for epilepsy in people with autism. 
Currently, however, the clinical cautions and the limited evidence base 
from which to draw treatment guidelines that apply when prescribing 
AEDs to people with ID also apply when prescribing AEDs for epilepsy 
management in people with autism. Choice of AED should, as for 
those with ID, be determined by similar considerations of seizure 
type, adverse-effect and drug-interaction profiles, and associated 
psychiatric and behavioural presentations. The presence of comorbid 
neurodevelopmental disorders such as autism or other pervasive 
developmental disorders (PDDs) may be an indication to initiate 
treatment early. There is a significant overrepresentation of seizures 
in this population. About 30–40% of children with autism develop 
clinical epilepsy by adolescence. The prevalence of epilepsy may be 
as high as 67% in children with comorbid autism, ID and cerebral 
palsy at the age of 10, and seizures continue to adulthood (Tuchman 
& Rapid, 2002). The remission rate for seizures in autism is low, 
at only 16% (Danielsson et al, 2005). The evidence of additional 
associations is extremely helpful in deciding a course of action when 
there is diagnostic ambiguity as to whether the presenting symptoms 
are of a seizure or not. 
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Dementia
There is a paucity of research into dementia and ID as, until recently, 
dementia did not have time to manifest itself, owing to the limited 
life expectancy of this population. As people with ID are now living 
longer, it has become apparent that they can develop many types 
of dementia. Early symptoms of dementia in people with ID are 
reported to be different from those experienced by the general 
dementia population. One specific area of symptom variation in ID 
is an increased prevalence of behavioural as opposed to cognitive/
memory changes. There is a well-established association between 
the emergence or worsening of seizures and progressive dementia 
in people with Down syndrome (Lott et al, 2012). 
As with the general population, people with ID are at risk of seizures 
secondary to cerebrovascular and metabolic events, among other 
precursors of dementia. Studies in the general population have shown 
that seizures or epilepsy are substantially more common in patients 
with dementia than in dementia-free patients and tend to be more 
frequent in advanced stages of the disease (Friedman et al, 2012; 
Pandis & Scarmeas, 2012). Many widely used drugs are known to 
potentially lower seizure threshold. Anti-dementia drugs such as 
cholinesterase inhibitors are proconvulsive (Caramelli & Castro, 2005), 
so before AEDs are considered any concomitant medication needs to 
be reviewed. No particular AED has been identified to have specific 
advantage for dementia-associated seizures. It is important that 
prescribing takes into account age-related changes in drug absorption 
and metabolism (Pohlmann-Eden & Eden, 2011). Sodium valproate, 
lamotrigine and levetiracetam are recommended as first-line AEDs, 
but it should be noted that levetiracetam can cause behavioural 
disturbances, lamotrigine must be slowly titrated and has potential 
for interaction and allergic reactions, and sodium valproate can cause 
tremor and thrombocytopaenia. 
Catamenial epilepsy
Catamenial epilepsy refers to an exacerbation of seizures linked to 
a woman’s menstrual cycle. Three patterns of hormonally based 
catamenial epilepsy have been identified (Herzog et al, 1997): 
perimenstrual, when oestrogens increase at a faster rate than 
progesterone; pre-ovulatory; and luteal phase, when progesterone 
is lower than normal during the ovulatory cycle owing to inadequate 
corpus luteal development.
Oestrogens are considered proconvulsant and progesterones 
anticonvulsant, and increased seizure frequency has been reported 
during the follicular phase, when oestrogen concentrations are at 
their highest (Backstrom, 1976). During anovulatory cycles, seizure 
frequency tends to be higher in the second half of the cycle (Herzog 
et al, 1997). It is important to note that actual catamenial epilepsy, 
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using a strict definition of ≥75% of seizures occurring within 4 days 
preceding and 6 days after the onset of menstruation, is less frequent 
than is actually reported (Duncan et al, 1993). 
Perimenstrual exacerbation of seizures may also be due to lower serum 
AED levels. This can certainly occur with phenytoin (Reddy 2010), but 
whether it can occur with other AEDs has not been adequately studied. 
In confirmed catamenial epilepsy, further investigations to inform 
treatment include measuring mid-luteal serum progesterone levels 
to check for luteal-phase deficiency in secretion. In a perimenstrual 
catamenial pattern, check trough AED levels on day 22 (when 
oestradiol and progesterone levels are high and AED levels should be 
‘normal’) and on day 1 (when oestradiol and progesterone levels are 
low). Low AED levels at this time (perhaps related to increased drug 
metabolism) might be the cause of perimenstrual seizure exacerbation 
(Klein & Herzog, 1997).
Evidence supports the use of clobazam for the management of 
catamenial epilepsy (Feely & Gibson, 1984). A dose of 10 mg at night 
during the perimenstrual period is often sufficient; for patients who 
are unable to tolerate this dose, administration of 10 mg on alternate 
nights could be considered, given clobazam’s long half-life.
Other options include increasing the dose of the AED around the 
time of risk or introducing acetazolamide for perimenstrual seizures. 
Particularly if premenstrual progesterone levels are low, hormonal 
manipulation using, for example, medroxyprogesterone could 
be considered. Progesterone therapy has been used with some 
success to increase relative progesterone concentrations or convert 
anovulatory to ovulatory cycles (Herzog, 1999). However, there is 
limited evidence for the effectiveness of these approaches in treating 
catamenial epilepsy. 
Ultimately, if catamenial epilepsy does not respond to any of the 
above measures, consider referring to endocrinology or gynaecology 
colleagues, for more specialist approaches to hormonal treatments.
Recording an epilepsy diagnosis 
Since multiple diagnoses and comorbidity are more the norm than 
the exception in people with ID, the recording of the diagnosis of 
epilepsy should be in the context of a detailed diagnostic assessment 
and formulation that covers all of the following (Faculty of Psychiatry 
of Intellectual Disability, 2016):
 z the degree of ID
 z the cause of the ID (including genetic syndromes, behavioural 
phenotypes)
 z other developmental disorders (including autism spectrum 
disorders, hyperkinetic disorder)
 z mental illnesses
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 z personality disorders
 z disorders related to substance misuse or dependence
 z physical disorders (including any of the causes of the ID)
 z psychosocial stressors (long-standing issues as well as recent 
environmental changes)
 z types of behaviours that challenge (in this structure, behaviours 
that challenge are not treated as a diagnosis, but as a presenting 
symptom in the context of a range of biopsychosocial factors).
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The NICE clinical guideline on epilepsies (CG137) clearly states that, 
when prescribing AEDs to people with ID, particular attention should 
be given to observing for any adverse cognitive or neuropsychiatric 
effects (NICE, 2012). 
Neuropsychiatric disturbance 
and challenging behaviour
Behavioural disturbance is often reported in the context of a new 
AED prescription or an increase in dose (Table 5). In a population in 
which epilepsy and behavioural problems are common, cause and 
effect is often very difficult to establish. Before any medication change 
it is often helpful to document baseline behaviours so that a more 
objective assessment may be possible following the introduction of 
Side-effects – challenging 
behaviour, physical and 
mental health





































Adapted and modified from Aldenkamp et al (2016).
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a new drug. If a change in behaviour type or frequency does take 
place, there are several possible causes other than medication. The 
behaviour may be the consequence of improved seizure control as 
the individual becomes more alert and responsive. A new AED may 
result in previously rapidly generalising focal epilepsy subsequently 
manifesting as an aura only, to which the individual may respond 
fearfully. There may be environmental causes, such as a change 
in carers or cohabitors, day care or residential/respite provision or 
the loss of a family member. More commonly, however, behavioural 
changes are a communication of emergent side-effects and these 
should be acknowledged and explored.
Cognition
Knowledge of the side-effect profiles of the various AEDs is essential, 
as people with ID may be particularly susceptible to developing 
adverse effects and less able to communicate about them. Adverse 
effects may be acute and usually dose related, idiosyncratic or linked 
to chronic administration. AEDs that are more commonly known to 
affect cognition, such as phenobarbitone or topiramate (Table 5), may 
require careful consideration before prescribing for an individual with 
ID. The prescriber must weigh the benefits of improved seizure control 
against the short- and long-term risks of side-effects.
Weight gain/loss
Several AEDs have been found to predispose to significant change in 
weight. In a population in which obesity is already common this should 
be considered before initiating treatment; valproate, gabapentin and 
pregabalin are potentially associated with weight gain. Conversely, 
anorexia can be a problem for a minority, and the prescription of 
topiramate or zonisamide may result in a loss of appetite and weight. 
Bone density
The development of osteoporosis is associated with chronic 
AED administration: decreased bone density has been reported 
with administration of phenytoin, phenobarbitone, primidone, 
carbamazepine and valproate (Farhar et al, 2002). This is of particular 
relevance to the ID population, as many will have significant coexisting 
risk factors for decreased bone density and fracture. Immobility, lack of 
exposure to sunlight, poor dietary intake of vitamin D, early menopause 
and co-prescription of antipsychotics are all more common among 
the ID population and may contribute to poor bone mineralisation. 
The exact mechanism by which AEDs predispose to osteoporosis is 
unclear: possibly it is through the enzymatic induction of vitamin D. 
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Other side-effects
The possibility of adverse physical effects from an AED, such as 
ataxia, diplopia or gastric irritation, should also be considered as an 
explanation for behavioural change. It is also important to be vigilant 
for side-effects such as neutropaenia and thrombocytopaenia. These 
should be suspected if, for example, there are recurrent infections, 
tiredness or falls. As the majority of people with ID are unable to 
represent their interests suitably and a significant number have 
problems in communication and comprehension, clinicians should 
consider annual monitoring of routine biochemistry based on the drugs 
prescribed, to recognise and treat any potential developing side-effect. 
We recommend that some or all basic tests such as blood pressure, 
body mass index, kidney function tests, liver function tests (LFTs), full 
blood count (FBC), glycated haemoglobin, and cholesterol and lipid 
profile be considered at least annually. Tests need to be rationalised on 
the basis of the specific side-effects of individual AEDs, their expected 
frequency, clinical presentation and anticipation. For example, people 
on carbamazepine will benefit from routine FBC and kidney function 
tests and those on sodium valproate from LFT and FBC. For people 
on chronic AED treatment and other medication, occasional dual 
energy X-ray absorptiometry (DEXA) scan and bone profile might 
be warranted to check on changes, especially at key junctures of 
life such as menopause. Similarly, electrocardiograms (ECGs) to 
look for change in heart function might be called on occasionally. 
Opportunity to conduct the investigations needs to be taken into 
account in people with ID. It would be good practice to ensure that 
a battery of investigations and tests identified as being in the best 
interests of the individual is done annually, or earlier if there is cause 
for concern (for example, easy bleeding when on sodium valproate). 
In those on whom it is difficult to conduct investigations (owing to 
the high levels of distress caused), good practice also suggests that, 
if they appear clinically well, an attempt be made to deliver relevant 
tests at least once every 3 years. 
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Many AEDs have a narrow therapeutic index. In 2013, the UK 
Commission on Human Medicines (CHM) reviewed adverse reactions 
reported to the Medicines and Healthcare products Regulatory 
Agency (MHRA) arising from prescription changing (switching) to 
generic formulations of AEDs in patients previously stabilised on 
branded products. As a result of the CHM’s recommendations, the 
MHRA (2013) advises that people prescribed certain AEDs should 
be maintained on the specific manufacturer’s product because of 
the risk of adverse effects or loss of seizure control when changing 
preparations. On the basis of therapeutic index, solubility and 
absorption, the MHRA groups AEDs are into three categories of 
potential risk on switching:
 z Category 1 (phenytoin, carbamazepine, phenobarbital, primidone) 
– prescribers should ensure that patients are maintained on a 
specific brand or a specific manufacturer’s generic product
 z Category 2 (valproate, lamotrigine, perampanel, retigabine, rufin-
a mide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, 
zonisamide, topiramate) – prescribers should decide whether it 
is necessary to maintain a patient on a particular manufacturer’s 
product on the basis of clinical judgement and consultation with 
the patient and/or carer, taking into account factors such as 
seizure frequency and treatment history 
 z Category 3 (levetiracetam, lacosamide, tiagabine, gabapentin, 
pregabalin, ethosuximide, vigabatrin) – it is unnecessary to 
maintain patients on a specific manufacturer’s product unless 
there are particular concerns such as patient anxiety or risk of 
confusion or dosing errors. 
Drug preparations  
and their relevance
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AEDs may interact with each other and with other medications. These 
interactions may be divided into three levels of importance (Table 6). 
In this chapter we give examples of common drug interactions that it 
is important to be aware of when prescribing AEDs (Patsalos, 2016). 
A full list of interactions of AEDs with other drugs can be found on the 
NICE BNF website (https://bnf.nice.org.uk/interaction).
Table 6 Levels of importance of interactions of anti-epileptics with other drugs and potential serious clinical 
consequences
Drug interaction Potential consequences
Level 1 interactions: Avoid combination as may lead to potentially serious adverse events
Examples
Carbamazepine/phenytoin/phenobarbitone/
primidone and oral contraceptive pill
Reduction in contraceptive effect
Carbamazepine and clarithromycin/erythromycin Elevated serum carbamazepine levels, resulting in 
toxicity
Lamotrigine and oral contraceptive pill Up to 50% reduction in serum lamotrigine levels 
and loss of seizure control; note: if a woman taking 
lamotrigine stops taking oral contraceptive, lamotrigine 
level will increase, so dose adjustment by up to 50% 
may be required to avoid toxicity
Lamotrigine and carbamazepine Carbamazepine often reduces the effects of 
lamotrigine, but lamotrigine sometime increases the 
effects of carbamazepine, so it is difficult to clearly 
attribute side-effects or even effectiveness to one or 
the other drug
Carbamazepine and clozapine Increased risk of agranulocytosis
Carbamazepine and lithium Neurotoxicity
Level 2 interactions: Caution advised in prescribing or any dose adjustments
Examples
Valproate and lamotrigine Elevated serum lamotrigine levels, resulting in skin rash, 
neurotoxicity




Reduced serum warfarin concentration
Carbamazepine/phenytoin/phenobarbitone/
primidone and ciclosporine
Reduced serum concentrations of ciclosporine, 
resulting in therapeutic failure
Level 3 interactions: Clinically relevant changes in serum concentrations unlikely
Adapted from Johannessen & Johannessen Landmark (2010).
Common drug interactions
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As well as interactions between AEDs it is important to be aware of 
potential interactions with medication prescribed by other clinicians.
Oral contraceptives 
One key example of interaction is with the oral contraceptive pill (OCP). 
Some methods of contraception may be less effective in preventing 
pregnancy for women taking certain AEDs (Reddy, 2010). This is 
because some AEDs are hepatic enzyme-inducing: they increase the 
metabolism of both progesterone and oestrogen and thus can affect 
how well the contraceptive works. Non-enzyme-inducing AEDs are 
unlikely to affect contraception. 
Carbamazepine, eslicarbazepine acetate, oxcarbazepine, pheno-
barbital, phenytoin, rufinamide, topiramate and perampanel are all 
hepatic enzyme-inducing and will have an impact on contraceptives. 
These drugs, especially carbamazepine, accelerate OCP metabolism, 
reducing contraceptive effect. Sodium valproate does not interfere with 
the oestrogen component of the contraceptive pill, unlike phenytoin 
and carbamazepine. 
Drugs such as levetiracetam, zonisamide, pregabalin, lacosamide, 
brivaracetam, clobazam and clonazepam are unlikely to effect OCPs. 
Lamotrigine needs to be considered as a special case with OCPs. 
It is a non-enzyme-inducing AED that can lower the amount of 
progestogen from an OCP but not the oestrogen. There is currently 
no conclusive evidence that lamotrigine reduces the effectiveness of 
OCPs, but there is evidence that OCPs lower lamotrigine levels in the 
blood. This could reduce seizure control and allow seizures to occur. 
It is important that any OCP and AED co-prescribing be considered 
carefully.
 z Is the interaction significant?
 z Should consideration be given to changing the AED dose or 
type? Could this lead to risk of losing seizure control? 
 z Should consideration be given to changing the type of 
contraception? If so, to what?
 z Have the benefits and risks of prescribing contraceptives together 
with AEDs been discussed comprehensively with the patient or 
in the best interests of the patient?
 z Has advice been taken from a pharmacist? 
In women with ID and epilepsy extreme care needs to be taken in 
prescribing and, more importantly, monitoring OCPs. Evidence-based 
pathways (Shankar et al, 2013b) should be considered to help support 
decision-making in prescribing and monitoring.
As discussed, there is a high rate of comorbidity in people with ID and 
epilepsy. Consequently, they are often co-prescribed psychotropic 
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medication for mental illness or behavioural disorders which may or 
may not be directly related to their epilepsy. It is therefore important 
for prescribers to be aware of the potential interactions that AEDs 
have with commonly prescribed psychotropic medications (Spina 
& Perucca, 2002; Johannessen & Johannessen Landmark 2010).
Psychotropic medication
Antidepressants and antipsychotics may inhibit or form substrates 
for a number of CYP enzymes. As a result, there is potential for 
interaction with the metabolic and therapeutic effects of AEDs (Spina 
& Perucca, 2002). 
Clozapine, olanzapine, risperidone, haloperidol, thioridazine, 
ziprasidone, quetiapine, citalopram and reboxetine act as CYP 
substrates.
Fluvoxamine, fluoxetine, paroxetine and sertraline are CYP inhibitors.
It is good practice to check the medication regime for any significant 
interactions, particularly when considering adding or withdrawing 
psychotropic medication. Such medication changes have the potential 
to affect the efficacy of AEDs and prescribers should consider 
checking serum drug levels where applicable.
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Antipsychotics
A study (Wu et al, 2016) comparing the antipsychotic-related seizure 
risk of first- and second-generation antipsychotics in patients with 
schizophrenia and mood disorders reported an overall 1-year incidence 
rate of 9.6 (95% CI 8.8–10.4) per 1000 person-years. First-generation 
antipsychotics were marginally associated with a higher seizure risk 
than second-generation antipsychotics (adjusted hazard ratio: 1.34; 
95% CI 0.99–1.81; P = 0.061), with certain antipsychotics having 
higher risk than others. Aripiprazole was found to have lower risk 
than risperidone (Table 7).
Antidepressants
Most antidepressants are regarded as being safe to prescribe for 
people with epilepsy (Johannessen Landmark et al, 2016). However, 
some, particularly older antidepressants, should be avoided or need 
to be used with caution as they have possible proconvulsant effects 
(Tables 8 and 9). 
The risk of seizures with most antidepressants is low, but it is probably 
not zero for any of them, and patients should be made aware of this 
Effects of commonly used 
psychotropics on seizures
Table 7 Significant antipsychotics associated with seizure risk 
compared with risperidone
Antipsychotic
Adjusted hazard ratio 
(95% CI)* Level of risk 
Clozapine 3.06 (1.40–6.71) Higher risk
Thioridazine 2.90 (1.65–5.10) Higher risk
Chlorprothixene 2.60 (1.04–6.49) Higher risk
Haloperidol 2.34 (1.48–3.71) Higher risk
Aripiprazole 0.41 (0.17–1.00) Lower risk
*P = 0.05.
Source: Wu et al (2016).
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Table 8 Seizure incidence rates and manufacturers’ advice for individual tricyclic antidepressants
Tricyclic antidepressant Incidence Manufacturers’ advice
Amitriptyline 0.3% (therapeutic doses) Avoid if possible in patients with a history of 
epilepsy
Clomipramine 0.5–12.2% (therapeutic doses, 
dose dependent)
Use with extreme caution in epilepsy (seizure 
occurrence appears to be dose dependent)
Dosulepin Limited data Avoid in patients with history of epilepsy
Doxepin 0.1% (therapeutic doses) Use with caution in patients with history of 
epilepsy
Imipramine 0.1% (≤ 200 mg/day),  
1.1% (>200 mg/day)
Use with extreme caution in epilepsy (seizure 
occurrence appears to be dose dependent)
Lofepramine Limited data Use with extreme caution in patients with a 
history of epilepsy or recent convulsions
Nortriptyline Limited data Avoid if possible in patients with a history of 
epilepsy
Trimipramine Limited data Use with great caution in patients with a history 
of epilepsy
Mianserin Limited data Convulsions have been reported at therapeutic 
dose so use with caution in epilepsy
Trazodone <0.1% (therapeutic doses) Use with caution in patients with epilepsy; 
specifically, avoid abrupt increases or decreases 
in dose
Source: UK Medicines Information (2016).
Table 9 Antidepressants by class and their seizure propensity
Antidepressant class Drug examples
Drugs with propensity to cause 
seizures and their metabolic pathway
Non-selective monoamine 
reuptake inhibitors (NSRIs): 
the TCA group
Amitriptyline, doxepin, nortriptyline, 
trimipramine 
Clomipramine (CYP1A2, 3A4, 2D6)
Selective serotonin reuptake 
inhibitors (SSRIs)
Citalopram, escitalopram, paroxetine, 
fluoxetine, fluvoxamine, sertraline 
Nonea
Noradrenaline reuptake 
inhibitors (NRIs) or 
serotonin–noradrenaline 
reuptake inhibitors (SNRIs)




Others Mianserin, mirtazapine Bupropion (CYP2D6)
a. SSRIs can have a proconvulsant effect in people without epilepsy, but this has not been shown in people with established 
epilepsy (Curran & de Pauw, 1998; Jackson & Turkington, 2005). Studies are largely in animal models and overdose in humans.
TCA, tricyclic antidepressant.
Source: modified from Johannessen Landmark et al (2016).
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when prescribing. The risk of seizures increases with increasing doses. 
Selective serotonin reuptake inhibitors (SSRIs) are considered the 
first-line antidepressant option in patients with epilepsy. Fluoxetine 
is not the best choice, because of its long half-life, a possibly greater 
incidence of seizures and an increased risk of drug interactions. 
Citalopram or sertraline may be considered better options, because 
of their safety and reduced interaction potential with AEDs.
As a general rule, the more sedating a drug is, the more likely it is 
to induce seizures (Taylor et al, 2015). There is a dose-dependent 
relationship between antidepressant use and seizures. Patients with 
a history of seizures should be started on a low dose, and this should 
be increased slowly until a therapeutic dose has been achieved (Taylor 
et al, 2015; Bazire, 2016). In addition, maximum recommended doses 
of antidepressants should not be exceeded.
Although it is possible that antidepressant drugs will lower the seizure 
threshold, this should not get in the way of appropriately treating 
a depressive disorder in an individual who also has epilepsy. Any 
changes in seizures should be noted and consideration given to a 
concomitant increase in AED dose.
Lithium 
Lithium is licensed for recurrent depression where treatment with other 
antidepressants has been unsuccessful (eMC, 2015). Lithium use in 
epilepsy is cautioned because of its potential to increase the frequency 
of convulsions at therapeutic doses and it has marked epileptogenic 
activity in overdose (eMC, 2015; Bazire, 2016). In addition, interactions 
with carbamazepine may cause neurotoxicity and there are reports 
of interactions with phenytoin (eMC, 2015). 
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The NICE clinical guideline on epilepsies (CG137) states that clinicians 
should help individuals with epilepsy and ID and their family or 
caregivers (if appropriate) to take an active part in developing a 
personalised care plan that takes any comorbidity into consideration 
(NICE, 2012: section 1.16). Reasonable adjustments should be 
made to ensure adequate time for consultation and individuals 
should have access to all applicable investigations and treatment 
options. The monitoring of effectiveness and tolerability of treatment 
should be the same as for the general population, but with particular 
attention paid to the potential adverse cognitive and behavioural 
effects of AEDs.
Clinicians should maintain high levels of vigilance for adverse effects 
of treatment, including bone health and neuropsychiatric problems. 
It is essential that an individual with epilepsy and ID and their family 
or carers, if appropriate, are fully informed about the treatment plan 
and any potential adverse effects. Adjustments should be made to 
facilitate understanding, including the use of communication aids and 
advice from other professionals. CG137 states that the maximum time 
between reviews should be 12 months. It would be good practice 
to provide a review at least every 3 months, particularly if there are 
ongoing changes to AEDs. This could be performed remotely, using 
methods such as telehealth or a telephone consultation.
Commencing and switching 
medication
NICE and the British National Formulary publish high-level evidence 
on the initiation of AEDs. However, all such advice is from trials 
and studies done in the general population. What is now becoming 
accepted is that any new AED prescribed for someone with ID needs 
to be started at a low dose, with the priority being to establish 
safety and mitigate side-effects as opposed to achieving quick 
efficacy. The likelihood of making a difference swiftly in a person 
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of the medication causing side-effects and being withdrawn without 
having a fair trial. It is essential to start a new AED and build it up to a 
therapeutic dose before withdrawing an old medication. It is prudent 
to start low, go slow and to co-prescribe the fewest possible different 
AEDs. Prescribing more than three is likely to raise the risks of side-
effects disproportionately to the benefits provided. If more than three 
AEDs are in the regime, a clear rationale must be given as to why that 
is the case and what is being done to reduce the number of AEDs, 
mitigate their long-term side-effects and justify the positive role of the 
regime. As already explained, comorbidities and other medications 
need to be considered when choosing an AED.
Managing medication
In the general population the goals of treatment are clear – seizure 
freedom, minimal side-effects and improved quality of life – and 
outcomes are easily assessed. Setting treatment goals and assessing 
outcomes are more challenging in people with ID, because of the 
complexity of their condition and the often treatment-resistant nature 
of their epilepsy. Nevertheless, the ideal is to establish treatment 
goals before starting treatment, even though they might subsequently 
prove to be unattainable. Goals should be discussed with the patient 
and, if appropriate, family or caregivers. The primary goal should be 
freedom from seizures, but if that is doubtful in practice, acceptable 
alternatives should be considered. Goals such as seizure reduction, 
improvements in cognition and improved quality of life may all be 
appropriate. In assessing outcomes, clinicians must balance the value 
of any change in seizure profile against any negative effects of AEDs. 
Over time, a balance between seizure control, cognitive function, 
behaviour and other factors may need to be agreed. 
An objective measure of treatment outcome is essential, in clinical 
and research settings. Outcome is a continual process and includes 
not only an assessment of seizure control, but also consideration 
of side-effects and quality of life. A number of barriers to effective 
evaluation may be present. Information will, by necessity, be largely 
inferred from people with limited communication skills and may be 
subject to ‘diagnostic overshadowing’. A multidisciplinary approach 
will be required in most cases to obtain reasonable-quality data, as 
many individuals will have multiple caregivers in a variety of settings, 
all requiring guidance to produce accurate recordings. 
For individuals with epilepsy and ID it is essential that clinicians 
consider a wider perspective. Epilepsy management is more than 
monitoring seizures. As clinicians we must take a holistic personalised 
approach to care. A diagnosis of epilepsy has a broader impact on 
quality of life, affecting psychological well-being and social functioning. 
We know that seizure control is not the main determinant of good 
clinical outcome (Boylan et al, 2004). The Glasgow Epilepsy Outcome 
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Scale (GEOS) is a useful easy-to-use instrument that may help capture 
a wide range of clinical and care concerns from individuals and 
their caregivers. Health practitioners and carers were involved in its 
development, and it has been shown to have validity and practical 
utility for clinicians (Espie et al, 2001). The GEOS may be used in 
conjunction with clinical assessment of seizure control and treatment 
outcome within the process of measuring change.
Individuals and their families or caregivers will have specific concerns 
about AEDs, particularly if the proposed medication may have cognitive 
or behavioural side-effects. Before prescribing, the clinician should 
clearly describe these potential effects when discussing treatment 
options. People with ID will often be on multiple therapies and will 
have tried several AEDs. It is important to place an individual on a 
treatment pathway that will assess all available treatment options, 
including those already in place. The first step is to appraise the current 
AED therapy. If there is inadequate epilepsy control, but evidence of 
efficacy and scope to increase the dose of AED, then do so while 
monitoring closely for adverse side-effects. If this is not successful, 
then remove the AED to avoid unnecessary polypharmacy. If the 
individual is prescribed multiple AEDs then remove any drugs that have 
demonstrated a lack of efficacy. If seizure control is still inadequate, 
the clinician should consider whether all ‘new’ AEDs have been trialled 
and also whether a surgical procedure is merited. 
Many people with ID have family members or caregivers who can 
help in giving treatment. The clinician will need to ensure that carers 
are capable of providing this support. The NICE guideline CG137 
(NICE, 2012) notes that these individuals may require formal training 
for this role. Seizure recording is important. However, specific help 
will be needed to count each type of seizure accurately, although it 
may be very hard to assess alteration in absences. 
Many people with ID and epilepsy are on repeat prescriptions of various 
medications from primary care to treat the significant comorbidity that 
is often present. It is important to ensure that drug regimes are closely 
monitored, and NHS England (2015, 2016) pledged to take action to 
address over-prescribing of psychotropic drugs to these individuals. 
The community or GP practice pharmacist can play a crucial role 
in ensuring that this happens, and medicines use reviews (MURs) 
can help this process (http://psnc.org.uk/services-commissioning/
advanced-services/murs).
As people taking multiple AEDs or those taking one AED for more 
than 5 years are at increased risk of bone loss (Pack & Morrell, 2004), 
and lower bone density is more prevalent among people with ID than 
in the general population, the primary care pharmacist can also help 
in promoting lifestyle measures to improve bone health and reduce 
the risk of osteopenia, osteoporosis and fractures associated with 
seizures (Centre for Pharmacy Postgraduate Education, 2017: pp. 
40–41).
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Drug monitoring
NICE guideline CG137 (NICE, 2012) states that routine drug monitoring 
is not recommended and should only be performed if there is an 
identified indication. For example, some AEDs (such as phenytoin) 
have a narrow therapeutic window secondary to zero-order kinetics 
and therefore there is a safety concern when adjusting the dose: if 
toxicity is suspected with such drugs, then blood serum levels should 
be checked. Serum levels should also be checked should there be 
any concern about toxicity with other AEDs. Other indications for 




Long-term feeding by PEG is uncommon but can present significant 
problems when both nutrition and medication have to be fed down 
the same tube. This is especially important in people with epilepsy, 
for whom the dose and bioavailability of AEDs is critical to maintaining 
adequate seizure control (Jory et al, 2017). In such cases, measuring 
the serum concentration of AEDs that have increased pharmacokinetic 
variability can have a valuable role (Patsalos et al, 2008). The Handbook 
of Drug Administration via Enteral Feeding Tubes (White & Bradman, 
2011) offers national guidance, and clinicians have a responsibility 
to ensure bioequivalence between formulations to avoid treatment 
failure or toxicity. If they do not have bioequivalence data to hand, 
we recommend that they liaise with a pharmacist or possibly with 
the drug company to obtain up-to-date details.
Withdrawing medication
NICE guideline CG137 (NICE, 2012) tells us that any decision to 
withdraw AEDs should be taken following detailed discussion with 
the individual, their family/carers and their epilepsy specialist. The 
specialist must manage the withdrawal. The risks and benefits of 
continuation or withdrawal must be explored in full for those who have 
been seizure free for at least 2 years (in some cases for up to 5 years). 
A number of cohort studies have examined the reduction of AEDs in 
the ID population. A study by the MRC Antiepileptic Drug Withdrawal 
Group (1991) demonstrated that ID is not necessarily a barrier to AED 
withdrawal: therapy was successfully withdrawn for 40% of seizure-
free individuals. 
Owing to the comparatively high incidence of refractory epilepsy in 
people with ID, many individuals will require lifelong treatment. 
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The decision to begin the slow withdrawal of medication must be 
based on an evaluation of the potential benefits of being on AEDs v. the 
risk of seizure recurrence on withdrawal. It may be difficult to quantify 
the potential benefits of medication withdrawal, and assessments of 
individuals and their particular circumstances are required. Similarly, 
the potential impact of seizure recurrence may vary widely between 
individuals and necessitates debate. It is estimated that withdrawing 
treatment probably doubles the risk of further seizures, with the 
greatest risk of recurrence in the 2 years immediately after withdrawal. 
The risk of further seizures varies widely, but a number of risk factors 
are thought to be associated with poorer outcomes. Individuals with 
severe ID and gross neurological deficits have a high probability of 
seizure recurrence. Those receiving AED polytherapy have a tendency 
to do worse on treatment withdrawal than those whose seizures 
have been controlled by a single drug (Medical Research Council 
Antiepileptic Drug Withdrawal Study Group, 1991). 
The withdrawal process should be underpinned by awareness 
of potential risks, including sudden unexpected death in epilepsy 
(assessed using structured evidence-based tools such as the SUDEP 
and Seizure Safety Checklist (https://sudep.org/checklist)), and the 
need for surveillance, especially at night. 
Capacity and consent
If there is concern that the individual lacks capacity to make treatment 
decisions, a capacity assessment under the Mental Capacity Act 2005 
must be completed. If the individual is deemed unable to give informed 
consent, then a best interests decision involving all key stakeholders, 
including if appropriate an independent mental capacity advocate, 
should be made. The views of the individual, their family and carers, 
and the multi-disciplinary team, must be carefully recorded.
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AEDs are the mainstay of treatment for epilepsy in individuals with 
ID. Appropriate skilled use should reduce the health inequalities 
experienced by this population. Professionals treating this population 
should recognise and acquire the appropriate knowledge and 
competencies necessary to deliver such skilled treatment. The WHO 
in its 2012 review concluded that ‘There is a paucity of good quality 
data on the choice of pharmacological and psychosocial interventions 
in this special population group, thus more research (intervention 
data, behavioural and cognitive safety) is needed in this population’ 
(World Health Organization, 2012: pp. 7–8). 
There is limited specific evidence to guide clinicians in the prescription 
of AEDs for people with epilepsy and ID. This document summarises 
the current evidence and provides informed opinion on prescribing 
that may be used to help guide prescribing practice. This is done 
with an acute awareness of the current gaps in our knowledge and 
in the evidence base. 
The primary concern of the clinician considering prescribing AEDs for 
someone with ID must be the principle ‘primum non nocere’ – first, 
do no harm. The risks and benefits of treatment and of no treatment 
should be discussed before prescribing, along with any potential 
adverse effects of medication. It is particularly important to establish 
whether the individual has the capacity to make informed decisions 
about their medical care: if they do not, the proposed treatment must 
be discussed with stakeholders in a best interests meeting. There is 
a rising awareness of the health and social needs of this vulnerable 
population, leading to an optimistic view that person-centred treatment 
evidence might be just round the corner.
Conclusion
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To treat or not to treat?
Vignette 1
James, who is 47 years of age, has severe ID, autism and well-
controlled epilepsy. Following his father’s death a year ago there was a 
relapse in seizures, which was put down to bereavement and changes 
in stress. However, after 6 months the seizures had not reduced 
despite increase in AEDs to which he had responded well in the past. 
A review by health and social care professionals that included a carer 
assessment revealed that James’s mother was struggling to cope 
with his needs, resulting in impairment in his daily quality of life and 
a lack of the day-to-day structure which used to stabilise his anxiety. 
A reassessment and review of his needs, with clear structuring of his 
daily activities, led to freedom from seizures again within 6 months 
without any further medication changes.
Vignette 2
Pauline is a 28-year-old with severe ID, autism and epilepsy who 
has attended the emergency department several times in the past 3 
months because of seizures. A holistic review showed that a person 
with terminal dementia had been moved to the room next to hers in 
the residential home. At night, the disturbances caused by this resident 
and the staff caring for her were interrupting Pauline’s sleep, making 
her more vulnerable to seizures. A move to a room in a quieter section 




Mary has Rett syndrome and severe to profound ID. She presented 
with brief apnoea attacks with no associated symptomology to 
aid diagnosis of whether these attacks were of seizure origin. She 
would not cooperate to have an ambulatory EEG. As there is seizure 
association of >90% in Rett syndrome, a trial of AED was attempted. 




AEDs and behavioural pitfalls
Vignette 4
Mark is 20 and has mild ID, transient mood disorder and Down 
syndrome. At his local hospital he was diagnosed with epilepsy and 
started on levetiracetam without full consideration of his psychological 
problems. With each increase in dose as advised by the BNF, the 
levetiracetam improved his seizures but worsened his mood and 
behaviour. He became aggressive and violent and was started on 
risperidone by his GP. This improved his behaviour, but caused a 
worsening of his seizures. Eventually, when referred to a specialist 
in ID and epilepsy, sodium valproate was commenced and titrated 
and, on stabilisation, the risperidone and levetiracetam were gradually 
withdrawn one by one. 
Vignette 5
Katie is a 48-year-old with severe ID and treatment-resistant epilepsy. 
When transferred to a service specialising in management of ID and 
epilepsy she was on 6 AEDs. Over a 3-year period her medication 
regime was rationalised to 2 AEDs. Levetiracetam was used as the 
‘stock’ AED and gradually increased. Four weeks after one such 
increase, services were contacted for an emergency review and 
possible reduction of levetiracetam because Katie’s behaviour had 
become challenging and she was refusing to undertake her personal 
hygiene routines. At the onsite enquiry it transpired that Katie’s 
challenging behaviour was specific to getting into the shower and 
was not generalised to other activities during the rest of the day. The 
team occupational therapist tested the shower and found that the 
hot water valve had failed. A subsequent investigation showed that 
the shower had been dysfunctional for over 6 months, but the highly 
sedative effect of the drugs that Katie had been on, and possible 
ongoing seizure activity, had reduced her awareness so she had not 
reacted. On rationalisation of her medication and improvement in 
her personal awareness she was acutely aware that the water was 
too hot and, lacking communication skills and being non-verbal, she 
remonstrated by exhibiting ‘challenging’ behaviour. Had the faulty 
valve not been noticed, this could have been wrongly attributed to 
the medication changes that had helped her become better. 
Complex case management
Vignette 6
Adam is 26 years old with a rare genetic syndrome leading to severe 
ID and epilepsy. The epilepsy has been in remission for over 4 years 
and he is on liquid levetiracetam. Owing to significant weight loss 
and its implications for Adam’s health, a percutaneous endoscopic 
gastrostomy (PEG) operation was done. He was recently referred with 
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concerns about relapse of seizures, even though the same medication 
was being delivered through the PEG. Initially, the seizures were 
thought to be an outcome of his physical health problems and the 
stress of surgery. However, when they did not abate a detailed enquiry 
was undertaken, including a best interests meeting that involved 
the pharmacist. The pharmacist found that the liquid levetiracetam 
formulation contained maltitol as a stabiliser, and this substance 
can speed up gut transit time. Thus, suboptimal efficacy might have 
been related to inadequate absorption in the gut. When switched to 
levetiracetam granules, which did not contain maltitol, there was swift 
improvement. In a short period Adam went back to seizure remission. 
Medication side-effects
Vignette 7
Susan, aged 46, has moderate ID with seizures that have been in 
remission for over 5 years; she is on sodium valproate 2000 mg/day 
and haloperidol. She presented with a 5-month history of lassitude, 
tiredness, falls and minor confusion, and having had three episodes 
of respiratory infection requiring antibiotic treatment. There was a 
recurrence of seizures with the infection and the GP believed this to be 
secondary to the high temperature occurring with the infection. Initially, 
it was thought that she might be going through the menopause. A full 
blood count among other blood tests revealed thrombocytopaenia. 
The sodium valproate was gradually reduced to 1500 mg/day and 
a re-test of full blood count after 3 months showed full recovery. 
Along with this, her problems of tiredness, infections, seizures and 
falls stopped.
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